Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2018; 10(9): 595-602
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.595
Published online Sep 27, 2018. doi: 10.4254/wjh.v10.i9.595
Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review
Eleni Gigi, Eleni Bekiari, 2nd Internal Medicine Department, Aristotle University Medical School, Hippokrateio General Hospital, Thessaloniki 54642, Greece
Vasileios I Lagopoulos, 5th Surgical Department, Aristotle University Medical School, Hippokrateio General Hospital, Thessaloniki 54642, Greece
Author contributions: All authors equally contributed to conception and design of the study, literature review and analysis. Gigi E and Lagopoulos VI composed the core of the manuscript and performed additional research, critical revision and editing; final review was equally managed by all authors; all authors approved the final version of the manuscript.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Eleni Gigi, MD, PhD, Academic Research, Assistant Professor, Hepatology Unit, 2nd Internal Medicine Department, Aristotle University Medical School, Hippokrateio General Hospital, Konstantinoupoleos 49, Thessaloniki 54642, Greece. elengigi@auth.gr
Telephone: +30-2313-312263 Fax: +30-2310-992794
Received: March 30, 2018
Peer-review started: March 30, 2018
First decision: May 11, 2018
Revised: May 25, 2018
Accepted: June 30, 2018
Article in press: June 30, 2018
Published online: September 27, 2018
Peer-review started: March 30, 2018
First decision: May 11, 2018
Revised: May 25, 2018
Accepted: June 30, 2018
Article in press: June 30, 2018
Published online: September 27, 2018
Core Tip
Core tip: Inability to reach sustained virological response (SVR) and cirrhosis are independent prognostic factors for developing hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) patients from the interferon (IFN) era. DAAs offer significantly better SVR rates. The first data regarding HCC occurrence after direct antiviral agent (DAA) treatment are similar to the data from patients who achieved SVR under IFN treatment. Some reports on early HCC occurrence or recurrence after DAA treatment are probably due to selection bias, as they were not reproduced in large comparative studies. DAAs can eradicate HCV, but they cannot terminate HCV-induced premalignant processes once triggered.